Vanguard Group Inc. Boosts Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Vanguard Group Inc. raised its stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 3.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,860,508 shares of the company's stock after purchasing an additional 92,791 shares during the quarter. Vanguard Group Inc. owned about 6.19% of 4D Molecular Therapeutics worth $15,933,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. KLP Kapitalforvaltning AS purchased a new stake in 4D Molecular Therapeutics during the fourth quarter valued at about $48,000. PNC Financial Services Group Inc. lifted its position in shares of 4D Molecular Therapeutics by 66.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company's stock worth $51,000 after purchasing an additional 3,630 shares in the last quarter. Daiwa Securities Group Inc. boosted its position in 4D Molecular Therapeutics by 5,291.8% in the 4th quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company's stock valued at $55,000 after buying an additional 9,737 shares during the last quarter. Fox Run Management L.L.C. acquired a new stake in 4D Molecular Therapeutics during the 4th quarter valued at approximately $69,000. Finally, AlphaQuest LLC grew its position in shares of 4D Molecular Therapeutics by 3,665.2% during the fourth quarter. AlphaQuest LLC now owns 14,835 shares of the company's stock worth $83,000 after buying an additional 14,441 shares in the last quarter. 99.27% of the stock is currently owned by institutional investors and hedge funds.

4D Molecular Therapeutics Price Performance

Shares of FDMT opened at $3.06 on Friday. The firm's 50 day moving average is $3.80 and its 200-day moving average is $5.94. 4D Molecular Therapeutics, Inc. has a 12-month low of $2.24 and a 12-month high of $28.93. The stock has a market capitalization of $141.68 million, a P/E ratio of -1.07 and a beta of 2.89.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its earnings results on Friday, February 28th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.10). As a group, equities research analysts forecast that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on FDMT. Bank of America lowered their price objective on 4D Molecular Therapeutics from $42.00 to $40.00 and set a "buy" rating for the company in a report on Monday, March 10th. Chardan Capital reduced their target price on shares of 4D Molecular Therapeutics from $30.00 to $28.00 and set a "buy" rating for the company in a research note on Tuesday, March 4th. Leerink Partners reduced their price target on 4D Molecular Therapeutics from $31.00 to $27.00 and set an "outperform" rating for the company in a research report on Monday, January 13th. BMO Capital Markets downgraded shares of 4D Molecular Therapeutics from an "outperform" rating to a "market perform" rating and dropped their price target for the stock from $40.00 to $15.00 in a research report on Monday, January 13th. Finally, HC Wainwright reiterated a "buy" rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, 4D Molecular Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $26.71.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.